Medicine and Dentistry
Head and Neck Squamous Cell Carcinoma
77%
Lung Cancer
75%
Wart Virus
71%
Cancer
69%
Epidermal Growth Factor Receptor
57%
Protein Tyrosine Kinase
50%
Aurora A Kinase
50%
Programmed Cell Death
46%
Immunotherapy
45%
Malignant Neoplasm
43%
EGFR Inhibitors
41%
Alisertib
36%
Phosphotransferase Inhibitor
33%
Cancer Therapy
30%
Upregulation
29%
Tyrosine-Kinase Inhibitor
29%
Cell Migration
29%
Tumor Progression
27%
Neoplasm
27%
Xenograft
27%
Immune Checkpoint Inhibitor
26%
Aurora Kinase
25%
Aurora B Kinase
25%
Mitogen Activated Protein Kinase 3
25%
Cell Invasion
25%
Tumor Cell
25%
Systemic Therapy
25%
Proteinase
25%
Cancer Model
25%
Ethinylestradiol Plus Norethisterone Acetate
25%
Drug Resistance
25%
Molecularly Targeted Therapy
25%
DNA Synthesis
25%
Low Drug Dose
25%
Connexin 43
25%
Immunity
25%
Pembrolizumab
25%
Antibiotics
20%
Retinoblastoma
20%
Diseases
20%
Phosphotransferase
16%
SOS Response
16%
Mutagenic Agent
16%
Metastatic Carcinoma
16%
In Vitro
16%
Cancer Cell
14%
Cytotoxic T-Cell
13%
Cell Proliferation
13%
Cancer Growth
13%
Targeted Therapy
12%
Keyphrases
Lung Cancer
53%
High-risk Human Papillomavirus (HR-HPV)
53%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
52%
Aurora Kinase A (AURKA)
50%
Aurora Kinase Inhibitor
30%
Third Generation
28%
Lung Tumor
28%
Induced Apoptosis
27%
Programmed Death-ligand 1 (PD-L1)
27%
Drug Resistance Strategies
25%
Therapeutic Development
25%
Lung Cancer Model
25%
Extracellular Signal-regulated Kinase 1/2
25%
Oxidative Stress
25%
Systemic Treatment
25%
ETS Proteins
25%
Tumor Cells
25%
Tyrosine Kinase Inhibitor
25%
Treatment Modalities
25%
HER3
25%
Connexin 43 (Cx43)
25%
TRIP13
25%
Antibody Inhibition
25%
Low-dose Radiation
25%
Nucleoporin
25%
Transcription Factor
25%
Sequential Treatment
25%
Phospholipase C
25%
PI3K Inhibitor
25%
Glucocorticoid Receptor
25%
Ewing Sarcoma
25%
Nucleocytoplasmic Transport
25%
Tumorigenicity
25%
Mutant Forms
25%
Kinase Inhibitor
25%
EGFR Inhibitors
25%
Receptor Tyrosine Kinase
25%
Stress Development
25%
Molecular Targeted Therapy
25%
Aggressive Breast Cancer
25%
Cell Invasion
25%
Notch1
25%
Egfr
25%
Cell Migration
25%
Teashirt
25%
Inhibition Efficacy
25%
Targeted Inhibition
25%
Immune Checkpoint Inhibitors
25%
Overexpression
22%
Retinoblastoma
18%
Pharmacology, Toxicology and Pharmaceutical Science
Lung Cancer
100%
Epidermal Growth Factor Receptor
87%
Head and Neck Squamous Cell Carcinoma
77%
Malignant Neoplasm
76%
Neoplasm
57%
Aurora A Kinase
50%
Protein Tyrosine Kinase
50%
Human Papillomavirus
46%
Immunotherapy
45%
Protein Tyrosine Kinase Inhibitor
37%
Alisertib
36%
Diseases
29%
Tumor Growth
27%
Monoclonal Antibody
27%
Immune Checkpoint Inhibitor
26%
Pancreas Adenocarcinoma
25%
Pancreas Cancer
25%
Systemic Treatment
25%
Osimertinib
25%
Aurora B Kinase
25%
Ewing Sarcoma
25%
Phosphotransferase Inhibitor
25%
Connexin 43
25%
Proteinase
25%
Glucocorticoid Receptor
25%
Pembrolizumab
25%
Cancer Model
25%
Cetuximab
21%
Trastuzumab
19%
Receptor
18%
Chimeric Protein
16%
Chemotherapy
15%
Phosphotransferase
14%
Cancer Growth
13%
Growth Factor
12%
Phosphoinositide Dependent Protein Kinase 1
11%
Immunogenic Cell Death
10%
Monotherapy
9%
Cyclic AMP Dependent Protein Kinase
9%
Mouse Model
8%
Reactive Oxygen Metabolite
8%
Drug Resistance
8%
Childhood Cancer
8%
Immunosuppressive Agent
7%
Combination Drug
7%
Clinical Trial
7%
Recurrent Disease
6%
Long Term Survival
5%
Programmed Death 1 Receptor
5%
CD8 Antigen
5%